Evidence map›Paper›PMID 42564030›Full record

ArticleFrontiers in oncology2026

Tumor-derived miR-126 promotes tumor progression through immune modulation beyond the local tumor environment.

Takashi Akazawa, Yu Mizote, Tomoya Ekawa, Satomi Yoshida, Yachiyo Kumamoto, Yoichiro Harada, Hisataka Ogawa, Shunichi Watanabe, Shingo Hatoya, Norimitsu Inoue and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Takashi AkazawaDepartment of Cancer Drug Discovery and Development, Research Center, Osaka International Cancer Institute, Osaka, Japan.
Yu MizoteDepartment of Cancer Drug Discovery and Development, Research Center, Osaka International Cancer Institute, Osaka, Japan.
Tomoya EkawaDepartment of Cancer Drug Discovery and Development, Research Center, Osaka International Cancer Institute, Osaka, Japan.
Satomi YoshidaDepartment of Cancer Drug Discovery and Development, Research Center, Osaka International Cancer Institute, Osaka, Japan.
Yachiyo KumamotoDepartment of Cancer Drug Discovery and Development, Research Center, Osaka International Cancer Institute, Osaka, Japan.
Yoichiro HaradaDepartment of Glyco-Oncology and Medical Biochemistry, Research Center, Osaka International Cancer Institute, Osaka, Japan.
Hisataka OgawaNitto Joint Research Department for Nucleic Acid Medicine, Research Center, Osaka International Cancer Institute, Osaka, Japan.
Shunichi WatanabeDepartment of Cancer Drug Discovery and Development, Research Center, Osaka International Cancer Institute, Osaka, Japan.
Shingo HatoyaDepartment of Advanced Pathobiology, Graduate School of Veterinary Science, Osaka Metropolitan University, Izumisano, Japan.
Norimitsu InoueDepartment of Molecular Genetics, Wakayama Medical University, Wakayama, Japan.
Hideaki TaharaDepartment of Cancer Drug Discovery and Development, Research Center, Osaka International Cancer Institute, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epidermal growth factor-like domain 7 (EGFL7) was discovered as an extracellular matrix protein with an EGF-like domain and angiogenic and vasculogenic functions. It has also been shown to play a role in immunological evasion of tumor cells through attenuation of extravasation of immune cells by reducing the expression of cell adhesion molecules on vascular endothelial cells. Furthermore, microRNA-126 (miR-126), which is encoded within the intron of

Indexed as

immune regulationmicroRNAnon-local immune modulationregulatory T-cell (Treg)tumor immunity

Identifiers

PMID42564030
PMCPMC13441819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.